Cold Genesys Announces Name Change to CG Oncology

On March 25, 2020 Cold Genesys, Inc. reported the company is changing its name to CG Oncology, Inc. effective immediately (Press release, Cold Genesys, MAR 25, 2020, View Source [SID1234555833]). The name change reflects the company’s overall vision and mission to treat a variety of oncology conditions. CG Oncology is a clinical-stage immuno-oncology company developing an oncolytic immunotherapy to combat bladder cancer and other solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The re-naming of our company to CG Oncology reflects an important step in our journey to build a leading oncology therapeutic company," said CG Oncology CEO Arthur Kuan. "We believe changing the name from Cold Genesys to CG Oncology will be far more universally accessible and emphasizes our goal to fight cancer globally. The name change will be incorporated across all aspects of our business in the relatively near future. This change also reflects CG Oncology’s progress, as the company has achieved significant scientific and corporate milestones in recent years, and provides a clear and direct path in the years ahead. We are investing heavily in the growth of our company, and we are all striving to develop treatments that will ultimately change and save lives."

Kuan added, "We continue development of our lead therapeutic candidate, CG0070, an oncolytic immunotherapy for the treatment of BCG-unresponsive, non-muscle-invasive bladder cancer. CG0070 is also being studied in other bladder cancer settings as well as other solid tumor types. In addition, different immune checkpoint inhibitors are being studied in combination with our oncolytic immunotherapy."